Phase III trial of albumin-bound paclitaxel [Abraxane] as second-line therapy in patients with pancreatic cancer.
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2011
At a glance
- Drugs Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Abraxis BioScience; Celgene Corporation
- 28 Jan 2011 Celgene Corporation added as company
- 07 Apr 2008 New trial record.
- 01 Apr 2008 This trial is expected to be initiated before the end of 2008.